Bethesda, MD, February 18, 2014 – Epidarex Capital, a leading international early-stage life science venture capital fund, has invested in Confluence Life Sciences Inc., a biotechnology company focused on the rapid discovery and development of drugs to address unmet needs in cancer and chronic inflammatory…
Edinburgh, United Kingdom, February 7, 2014. Epidarex Capital, a leading international early-stage life science venture capital fund, has announced a £4 million Series A investment, in Edinburgh Molecular Imaging (EMI). Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round. EMI, an…
Louisville, Kentucky – August 21st, 2013 – Rock Spring Ventures has increased its investment in Apellis Pharmaceuticals Inc., an early-stage biotechnology company focused on developing a novel pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development. Apellis…
Edinburgh, United Kingdom – January 21st 2013 – Rock Spring Ventures today launched a unique £50m venture capital fund focusing on early-stage life science and health technology companies. Based in Scotland, the fund will invest in young companies developing novel approaches to unmet needs in…